Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Glucose Metabolism, Schizophrenia, and Antipsychotic Drugs: Comments to the Paper of Dwyer et al.

Glucose Metabolism, Schizophrenia, and Antipsychotic Drugs: Comments to the Paper of Dwyer et al. P1: FPX/FPQ/HGL P2: GVK/GAQ QC: GDR Annals of Clinical Psychiatry (ACLI) PP371-368903 March 6, 2002 11:16 Style file version Nov. 07, 2000 ° C Annals of Clinical Psychiatry, Vol. 13, No. 4, December 2001 ( 2002) Glucose Metabolism, Schizophrenia, and Antipsychotic Drugs: Comments to the Paper of Dwyer et al. 1, 2, 3 2 Trino Baptista, MD, PhD, and Serge Beaulieu, MD, PhD, FRCPC The effects of APs on glucose metabolism are, We welcome the recent paper of Dwyer et al. (1). thus, far from uniform and may be modulated by the It represents a valuable effort to further understand nutritional status and the specific mental disorder. the complex relationship between antipsychotic drugs Specifically, experimental conditions that promote (APs), glucose metabolism, schizophrenia and some weight gain in female rats may induce normal or low movement disorders. An important section of the paper discusses the serum glucose levels (because of normal or high in- effects of conventional and novel APs on glucose reg- sulin sensitivity). During acute experiments (which ulation in humans and animals. From the literature may impose a high level of stress) and with the use review conducted by the authors, it is concluded that of male rats, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Glucose Metabolism, Schizophrenia, and Antipsychotic Drugs: Comments to the Paper of Dwyer et al.

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/glucose-metabolism-schizophrenia-and-antipsychotic-drugs-comments-to-SgPGWSfi0t
Publisher
Springer Journals
Copyright
Copyright © 2001 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1014633503039
Publisher site
See Article on Publisher Site

Abstract

P1: FPX/FPQ/HGL P2: GVK/GAQ QC: GDR Annals of Clinical Psychiatry (ACLI) PP371-368903 March 6, 2002 11:16 Style file version Nov. 07, 2000 ° C Annals of Clinical Psychiatry, Vol. 13, No. 4, December 2001 ( 2002) Glucose Metabolism, Schizophrenia, and Antipsychotic Drugs: Comments to the Paper of Dwyer et al. 1, 2, 3 2 Trino Baptista, MD, PhD, and Serge Beaulieu, MD, PhD, FRCPC The effects of APs on glucose metabolism are, We welcome the recent paper of Dwyer et al. (1). thus, far from uniform and may be modulated by the It represents a valuable effort to further understand nutritional status and the specific mental disorder. the complex relationship between antipsychotic drugs Specifically, experimental conditions that promote (APs), glucose metabolism, schizophrenia and some weight gain in female rats may induce normal or low movement disorders. An important section of the paper discusses the serum glucose levels (because of normal or high in- effects of conventional and novel APs on glucose reg- sulin sensitivity). During acute experiments (which ulation in humans and animals. From the literature may impose a high level of stress) and with the use review conducted by the authors, it is concluded that of male rats,

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 19, 2004

References

  • Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment
    Dwyer, DS; Bradley, RJ; Kablinger, AS; Freeman, AM
  • Mechanism of the neurolepticinduced obesity in rats
    Baptista, T; Teneud, L; Contreras, Q; Albornoz, MA; Paez, X; de Quijada, M; Hernàndez, L
  • Glucose tolerance and serum insulin levels in an animal model of obesity induced by subacute or chronic administration of antipsychotic drugs Prog
    Baptista, T; Alvarez, L; LaCruz, A; de Mendoza, S; Hernández, L
  • Antipsychotic drug-induced obesity in rats: Correlation between leptin, insulin and body weight during sulpiride treatment
    Lacruz, A; Baptista, T; de Mendoza, S; Mendoza-Guillén, JM; Hernández, L
  • Low blood glucose and olanzapine
    Budman, CL; Gayer, BA